Guangzhou, China

Xiuping Lin

This inventor holds 1 USPTO granted patent. Top assignee: Chinese Academy of Sciences. Active years: 2017.


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiuping Lin: Innovator in Anti-Inflammatory Drug Development

Introduction

Xiuping Lin is a prominent inventor based in Guangzhou, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anti-inflammatory drugs. His innovative work has the potential to impact the treatment of various inflammatory conditions.

Latest Patents

Xiuping Lin holds a patent for a compound known as Strepsesquitriol A. This invention includes a preparation method and application for the compound, which is characterized by its ability to strongly inhibit the formation of LPS-induced TNFα without exhibiting cytotoxic activity. The significance of this compound lies in its potential use as a precursor for anti-inflammatory drugs, making it a valuable candidate for the treatment of multiple inflammations. The patent highlights the importance of developing Chinese marine drug resources.

Career Highlights

Xiuping Lin is affiliated with the Chinese Academy of Sciences, where he conducts his research and development work. His career is marked by a commitment to advancing the field of pharmacology and contributing to the discovery of new therapeutic agents.

Collaborations

Xiuping Lin collaborates with notable colleagues, including Xianwen Yang and Kun Peng. Their combined expertise enhances the research efforts at the Chinese Academy of Sciences and fosters innovation in drug development.

Conclusion

In summary, Xiuping Lin is a key figure in the field of anti-inflammatory drug research, with a focus on innovative compounds like Strepsesquitriol A. His work not only contributes to scientific knowledge but also holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…